Hence, it was speculated that Asprosin might be a target candidate for dysregulation of hepatic immunity in the progression of NAFLD, which might also imply the potential therapeutic value of Asprosin in inflammatory and immune disorders. The gene discussed is FBN1; the disease is metabolic dysfunction-associated steatotic liver disease.